Delving into the Latest Updates on CN54ENV DNA(Imperial College London) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Imperial College London

Active Organization-

Inactive Organization

Imperial College London

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

CUTHIVAC002 is a randomised Phase I study aimed at exploring the safety and immunogenicity of two different modes of delivery of a deoxyribonucleic acid (DNA) vaccine (DNA-C CN54ENV) via combined intramuscular and intradermal methods with and without electroporation, and boosted with recombinant HIV CN54gp140 administered by intradermal injection in healthy volunteers.
The aim of this study is to identify optimal DNA delivery conditions for promoting enhanced antibody responses to boosting with recombinant protein by the intradermal method.

Start Date11 Aug 2016

Sponsor / Collaborator

Imperial College London

[+1]

NCT03663998

/ CompletedPhase 1IIT

DNAVAC 001: A Phase 1 Open-labelled Trial to Optimise DNA Vaccination for Antibody Induction

This is a two part study to evaluate the immunogenicity and tolerability of DNA-C CN54ENV plasmid DNA (CN54ENV) administered with electroporation (EP), with and without DNA encoding recombinant interleukin-12 (GENEVAX® IL-12). Part 1 is exploratory and designed to select conditions capable of promoting enhanced B cell responses in a limited number of volunteers. Part 2 is dependent upon Part 1 and is designed to study the fine specificity of the B-cell immune responses to CN54ENV DNA in an expanded number of subjects. Data from both stages will be combined for safety and immunological analysis.

Start Date15 Aug 2015

Sponsor / Collaborator

Imperial College London

[+1]

100 Clinical Results associated with CN54ENV DNA(Imperial College London)

Login to view more data

100 Translational Medicine associated with CN54ENV DNA(Imperial College London)

Login to view more data

100 Patents (Medical) associated with CN54ENV DNA(Imperial College London)

Login to view more data

100 Deals associated with CN54ENV DNA(Imperial College London)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	-	Imperial College London	15 Aug 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02589795 (CTgov)	Phase 1	HIV Infections	28	Trigrid Delivery System - Intradermal+DNA-C CN54ENV+CN54gp140 (Group 1: ID/EP + IM)	ajmgxkcqju(spjkcmbghg) = odkzangyel mnnoxcwpzt (zcxjnhyafr, tnokvtyvde - xtcwnhydhl) View more	-	31 Jan 2025
				Trigrid Delivery System - Intramuscular+DNA-C CN54ENV+CN54gp140 (Group 2: ID + IM/EP)	ajmgxkcqju(spjkcmbghg) = opiogrvlhq mnnoxcwpzt (zcxjnhyafr, tkoyfwtofs - nfenrntskp) View more